Guest Seminar: Dr. Florian Freudenberg

    November 6th at 13:00
    Turku Bioscience, 5th floor Seminar Room, BIO 5017a, BioCity Turku

    Dr. Florian Freudenberg, Frankfurt University Hospital, Germany
    “Targeted disruption of NOS1AP interactions as a potential novel treatment in schizophrenia”

    Host: Michael Courtney, Turku Screening Unit and Neuronal Signalling Lab

    Florian Freudenberg is an  independent research group leader in the Laboratory of Translational Psychiatry at the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy of the University Hospital Frankfurt (Germany). His group studies the molecular mechanisms involved in the pathophysiology of mental disorders, with a particular emphasis on synaptic protein interactions relevant to schizophrenia, mood disorders and ADHD. Currently, his main line of research focuses on protein-protein interactions of NOS1AP – a neuronal scaffolding protein –  and selective targeting of these protein interactions as a potential novel treatment for schizophrenia.

    Selected recent publications

    Esen-Sehir D, Courtney MJ, Bittner RA, Reif A, Freudenberg F. Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice. Acta Neuropsychiatr. In press. doi: 10.1017/neu.2019.31.

    Grünewald L, Chiocchetti AG, Weber H, Scholz CJ, Schartner C, Freudenberg F, Reif A. Knockdown of the ADHD Candidate Gene Diras2 in Murine Hippocampal Primary Cells. J Atten Disord. In press. doi: 10.1177/1087054718822129.

    Candemir E, Kollert L, Weißflog L, Geis M, Müller A, Post AM, O’Leary A, Harro J, Reif A, Freudenberg F (2016). Interaction of NOS1AP with the NOS-I PDZ domain: Implications for schizophrenia-related alterations in dendritic morphology. Eur Neuropsychopharmacol. 2016 Apr;26(4):741-55. doi: 10.1016/j.euroneuro.2016.01.008.

    — Turku Bioscience Centre,University of Turku and Åbo Academy University,Biocity,Tykistökatu 6,Turku FIN-20520FINLAND Lab page Unit +358 (0) 294503739, +358 (0)504649827